The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community
ContributorsGaribotto, Valentina
Published inEuropean journal of nuclear medicine and molecular imaging, vol. 48, no. 10, p. 3033-3036
Publication date2021-09
Keywords
- Alzheimer Disease / diagnostic imaging
- Alzheimer Disease / drug therapy
- Humans
- Nuclear Medicine
Affiliation entities
Funding
- Swiss National Science Foundation - The Biological Basis of Cognitive Impairment due to Suspected Non-Alzheimer’s Pathology (SNAP) : Studying the interplay between amyloidosis and tau-related neurodegeneration [320030_169876]
- Swiss National Science Foundation - Individual cognitive risk profiling in aging according to Amyloid, Tau and Neurodegeneration imaging biomarkers [320030_185028]
- Swiss National Science Foundation - Strategic roadmap for the translation of tau biomarkers in the clinic: an international task force [IZSEZ0_188355]
- Velux foundation [project 1123]
Citation (ISO format)
GARIBOTTO, Valentina et al. The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community. In: European journal of nuclear medicine and molecular imaging, 2021, vol. 48, n° 10, p. 3033–3036. doi: 10.1007/s00259-021-05485-y
Main files (1)
Article (Published version)
Identifiers
- PID : unige:160677
- DOI : 10.1007/s00259-021-05485-y
- PMID : 34272989
Additional URL for this publicationhttps://link.springer.com/article/10.1007/s00259-021-05485-y
Journal ISSN1619-7070
